BioCentury
ARTICLE | Finance

Ebb & Flow

July 5, 2004 7:00 AM UTC

Three European companies picked their markets last week and two have hedged their bets by looking to NASDAQ as well as their home markets.

Cell cycle company Cyclacel said on Friday that it plans to go public via a dual listing on London and NASDAQ. For the U.K. company, the advantage of NASDAQ is the potential for raising future funds and being in the same environment as its close competitors. ...